. 2020 Sep 16;10:15218. doi: 10.1038/s41598-020-72292-0

Table 3.

Changes in urinary cytokines, functional proteins, and growth factors in IC/BPS patients with successful and failed treatment with repeat platelet-rich plasma (PRP) injections.

	GRA ≥ 2 (n = 27)	GRA < 2 (n = 13)	p value	Δp value
NGF_BL	0.29 ± 0.04	0.29 ± 0.04	0.911	0.428
NGF_Tx	0.21 ± 0.18	0.28 ± 0.12	0.174	0.428
BDNF_BL	0.52 ± 0.28	0.45 ± 0.1	0.276	0.821
BDNF_Tx	0.48 ± 0.45	0.54 ± 0.5	0.656	0.821
TGFB_BL	10.2 ± 12.2	18.0 ± 22.9	0.323	0.799
TGFB_Tx	7.67 ± 1.89	12.8 ± 17.2	0.370	0.799
PDGF-AA_BL	31.2 ± 29.9	48.3 ± 38.2	0.148	0.832
PDGF-AA_Tx	32.1 ± 25.1	51.8 ± 32.4	0.062	0.832
PDGF-AB_BL	2.44 ± 0.9	3.61 ± 2.39	0.150	0.534
PDGF-AB_Tx	4.15 ± 3.12	4.64 ± 2.44	0.661	0.534
MMP-13_BL	28.5 ± 20.2	24.0 ± 4.65	0.426	0.251
MMP-13_Tx	16.4 ± 3.83	19.5 ± 3.68	0.040	0.251
MMP-1_BL	25.3 ± 39.1	14.4 ± 5.86	0.399	0.530
MMP-1_Tx	14.3 ± 20.5	11.0 ± 6.29	0.625	0.530
IL-2_BL	0.74 ± 0.28	0.58 ± 0.10	0.012	0.620
IL-2_Tx	0.69 ± 0.26	0.58 ± 0.18	0.201	0.620
IL-6_BL	3.43 ± 7.45	1.02 ± 0.69	0.231	0.842
IL-6_Tx	3.8 ± 7.42	1.49 ± 0.99	0.316	0.842
IL-8_BL	23.7 ± 39.1	10.8 ± 12.8	0.216	0.869
IL-8_Tx	32.3 ± 56.6	15.2 ± 10.8	0.334	0.869
VEGF_BL	18.5 ± 7.15	15.7 ± 5.27	0.170	0.157
VEGF_Tx	0.1 ± 0.31	0.09 ± 0.13	0.904	0.157
IL-1β_BL	0.95 ± 1.21	0.77 ± 0.85	0.655	0.833
IL-1β_Tx	0.72 ± 0.24	0.63 ± 0.06	0.101	0.833
TNFα_BL	0.97 ± 0.97	0.74 ± 0.05	0.543	0.658
TNFα_Tx	1.57 ± 2.08	1.01 ± 0.24	0.415	0.658

GRA global response assessment, BL baseline, Tx post-PRP treatment, PRP platelet rich plasma, NGF nerve growth factor, BDNF brain-derived neurotrophic factor, TGF-β1 transforming growth factor beta 1, PDGF platelet-derived growth factor, MMP matrix metalloproteinase, IL interleukin, VEGF vascular endothelial growth factor, TNFα tumor necrosis factor α.